A randomized, open-label, blank-controlled, multi-center clinical study for Lian-Hua Qing-Wen Capsule/Granule in the treatment of asymptomatic patients with novel coronavirus pneumonia
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2100004336
- Lead Sponsor
- Hebei Province Chest Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Asymptomatically infected with novel coronavirus pneumonia discovered through pathogenic testing;
2. Over 18 years old (including 18 years old);
3. Voluntarily sign a written informed consent before the study begins.
1. Patients with new coronavirus pneumonia confirmed by pathogenic testing and clinical manifestations or signs;
2. In the opinion of the investigatorpatients with serious diseases such as malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine disease may affect patients' participation in the trial or influence the outcome of the study;
3. Pregnant or lactating women;
4. Patients who participated in other clinical trials within the last 3 months;
5. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;
6. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The time and rate of nucleic acid turning negative during the isolation observation period;
- Secondary Outcome Measures
Name Time Method Clinical symptoms and severity during the isolation observation period;Proportion of mild and common cases of novel coronavirus pneumonia diagnosed during the isolation observation period;Clinical symptoms appearance time and proportion during the isolation observation period;